Congestive Heart Failure Treatment Devices Market Expected to Achieve 7.8% CAGR by 2029: Growth Forecast Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Congestive Heart Failure Treatment Devices Market Size By 2025?
The market for devices used in the treatment of congestive heart failure has seen significant growth in the past few years. It's projected to expand from $19.61 billion in 2024 to $21.21 billion in 2025, with a compound annual growth rate (CAGR) of 8.1%. The previous growth can be credited to a move towards less intrusive surgical methods, increased demand for minimally invasive heart devices, ongoing educational and training programs for healthcare professionals, increased spending on healthcare, and a surge in patient preference for non-surgical or less invasive treatment alternatives.

How Big Is the Congestive Heart Failure Treatment Devices Market Size Expected to Grow by 2029?
The market of devices for the treatment of congestive heart failure is anticipated to witness robust growth in the coming years, reaching a value of $28.64 billion in 2029, expanding at a compound annual growth rate (CAGR) of 7.8%. The growth throughout the forecast period can be accredited to the rising aged population, escalating consciousness regarding cardiovascular health, the establishment of screening programs, beneficial repayment policies for structural heart surgeries, and prompt approval regulations for novel structural heart devices. Major trends expected during the forecast period include the increasing preference for transcatheter valve replacement, continuous development of innovative devices using sophisticated materials, the growing focus on bespoke treatment strategies, the progressive adoption of hybrid procedures, and the incorporation of remote healthcare monitoring and telehealth solutions.

View the full report here:
https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-treatment-devices-global-market-report

Which Key Market Drivers Powering Congestive Heart Failure Treatment Devices Market Expansion and Growth?
The escalating incidence of cardiovascular diseases is anticipated to fuel the expansion of the market for congestive heart failure treatment devices. Cardiovascular maladies constitute a variety of disorders impacting the heart and blood vessels, including hypertension, heart failure, and coronary artery disease, which can negatively affect heart function and blood circulation. This increased incidence is primarily associated with rising levels of risk factors such as poor dietary choices, sedentary lifestyles, obesity, and an aging demographic. Devices used for treating congestive heart failure play a key role in managing these conditions, notably by controlling heart rhythms and optimizing cardiac function, hence significantly boosting the prognosis for patients. For example, a report by Charity today, a charitable entity based in the UK, noted in January 2024 that over 39,000 premature deaths in England during 2022 were due to cardiovascular ailments such as heart attacks, coronary heart disease, and stroke. Thus, this growing incidence of cardiovascular diseases is propelling the expansion of the market for congestive heart failure (CHF) treatment devices.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15774&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Congestive Heart Failure Treatment Devices Market?
Major firms in the congestive heart failure treatment device market are engineering innovative global solutions such as dual-chamber leadless pacemakers aimed at enhancing heart rhythm coordination, lowering potential hazards linked to standard pacemaker leads, increasing patient comfort, and providing more efficient control over heart failure symptoms. This, in turn, improves the patient's quality of life and minimizes cases of hospital readmissions for arrhythmia patients. Dual-chamber leadless pacemakers are an upgraded pacemaker version designed to manage heart rhythm without resorting to the regular leads typically embedded in the heart. For instance, in February 2022, a prominent healthcare company based in the USA, Abbott Laboratories, successfully implanted the world's inaugural dual-chamber leadless pacemaker during a crucial clinical test. This revolutionary device, developed to control heart rhythms without regular leads, bolsters patient treatment by opting for less invasive methods. The device's dual-chamber design simplifies the simultaneous pacing of the atrium and ventricle, providing better control over heart conditions. This new technology aims to offer patients a more comfortable and effective approach to heart rhythm abnormalities, potentially decreasing hospital visits, and improving overall quality of life. The device's efficacy is observed through cutting-edge technologies, guaranteeing continued surveillance of cardiac health.

What Are the Emerging Segments in the Congestive Heart Failure Treatment Devices Market?
The congestive heart failure treatment devices market covered in this report is segmented -

1) By Product: Cardiac Pacemaker, Implantable Cardioverter Defibrillators (ICDs), Cardiac Resynchronization Therapy Devices (CRT), Counter Pulsation Devices, Ventricular Assist Devices (VADs)
2) By Application: Left Ventricular Assist Device (LVAD), Right Ventricular Assist Device (RVAD), Biventricular Assist Device (BIVAD)
3) By End-User: Hospitals And Clinic, Specialized Cardiovascular Disease Treatment Centers, Ambulatory Surgery Centers

Subsegments:
1) By Cardiac Pacemaker: Single Chamber Pacemaker, Dual Chamber Pacemaker, Biventricular Pacemaker
2) By Implantable Cardioverter Defibrillators (ICDs): Traditional ICDs, Subcutaneous ICDs, CRT-D (Cardiac Resynchronization Therapy Defibrillator)
3) By Cardiac Resynchronization Therapy Devices (CRT): CRT-P (Cardiac Resynchronization Therapy Pacemaker), CRT-D (Cardiac Resynchronization Therapy Defibrillator)
4) By Counter Pulsation Devices: Intra-Aortic Balloon Pumps (IABP), External Counterpulsation Devices (ECP)
5) By Ventricular Assist Devices (VADs): Left Ventricular Assist Devices (LVAD), Right Ventricular Assist Devices (RVAD), Biventricular Assist Devices (BiVAD)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15774&type=smp

Who Are the Global Leaders in the Congestive Heart Failure Treatment Devices Market?
Major companies operating in the congestive heart failure treatment devices market are Abbott Laboratories, Medtronic plc, Baxter International Inc., Boston Scientific Corporation, Terumo Corporation, Edwards Lifesciences Corporation, Charles River Laboratories International Inc., W. L. Gore & Associates Inc., Bracco Group, LivaNova PLC, Meril Life Sciences Pvt. Ltd., Biotronik SE & Co. KG, CryoLife Inc., HeartWare International Inc., Direct Flow Medical Inc., Berlin Heart GmbH, CVRx Inc., Micro Interventional Devices Inc., Jarvik Heart Inc., CardioKinetix Inc., Xeltis AG, Ancora Heart Inc., ReliantHeart Inc.

Which are the Top Profitable Regional Markets for the Congestive Heart Failure Treatment Devices Industry?
North America was the largest region in the congestive heart failure treatment devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure treatment devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15774

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.